|
Life Science Nation Newsletter | December 11, 2014 | Issue 92
|
|
 Life Science Investor Mandates (Dec. 4 - Dec. 10) |
| |
|
Seeking Global, Seed Stage, Software Enabled Device and HIT Opportunities
|
Seeking Early Stage 505(b)(2) Therapeutics
|
|
Looking for Clinical Stage Devices and Therapeutics
|
|
Do You Have the Right Investor List?
|
Diagnostic Landscape: Imaging and In Vitro Technologies
|
Panel announcements: Preclinical Investors and Healthcare IT
|
|
|
 |
|
 Companies often tell us that they were given a "qualified list" of investors by their investment bank, board, or consultant. And just as often, companies are surprised when LSN staff tell them that from our experience such lists typically have tenuous value, as they're not truly qualified. Recently, a potential client asked us to a review a list of investors that was provided by his investment bank. One must remember that data comes in two states, out-of-date and very-out-of-date. When an entity boasts about their investor stable or network the most important question is "How up to date is that data?" The next question should be "How many of the investors in your network have current, actionable mandates?" Those questions will quickly separate the real players that truly understand their investor base from those that simply talk a good game. To prove out the aforementioned point we actually asked for a list and then vetted the list against the LSN investor database and then showed the difference in share numbers that you get when using a real investor database versus a list that isn't curated. Please read on to get the LSN assessment...
|
 |
|
|
|
By Shaoyu Chang, MD, MPH, Senior Research Analyst, LSN
 The global diagnostics market continues to show robust growth, fueled by aging populations and rising awareness of the value of preventive care. In our recent series of articles, we've explored the therapeutic space for cardiovascular diseases, neurology, and oncology. This week, we dive into the diagnostics innovation and investor landscape.
Two major categories stand out in this space: diagnostic imaging devices and in vitro diagnostics (IVD). Diagnostic imaging devices claimed a global market of US$25.7 billion in 2013, with an estimated annual growth rate of 5.7% for the coming six years. More impressively, IVD claimed a US$47.3 billion global market in 2013, with an annual estimated growth rate of 7.3%...
|
|
|
|
By Tom Crosby, RESI Conference Manager, LSN
This week, LSN announces two panels for the upcoming Redefining Early Stage Investments Conference: Preclinical and Healthcare IT.
Panel Announcement #1: Preclinical
Moderated by Rajesh Rangantahn, Director of the Office of Translational Research for the NINDS, the audience will hear from:
- Michael Recny, CEO, Calvert Holdings
- Natalie Dakers, President and CEO, CDRD
- David Berry, Partner, Flagship Ventures
- Ron Demuth, President, Torrey Pines Investments
Panel Announcement #2: Healthcare IT
Moderated by Randy Scott, Partner, HealthQuest Capital, the audience will hear from:
- Akhil Saklecha, Partner, Artiman Ventures
- Rich Simoni, Partner, Asset Management Ventures
- Rik Vandevenne, Director, River Cities Capital Fund
- Phillip Sanger, Managing Partner, Texo Ventures...
|
|
|
|
|
|
Editors:
Nono Hu, Senior Manager, Branding & Messaging, LSN
|
|
|
|
